Sign in to continue:

Monday, April 20th, 2026

Agilent Technologies, Inc. Q1 2026 Quarterly Financial Report – Revenue, Earnings, and SEC Filings Highlights

Summary of Financial Results

  • Quarter Ended: January 31, 2026
  • Form Type: 10-Q Quarterly Report (Filed with the SEC)
  • Common Stock Outstanding: 294,602,317 shares as of February 25, 2026
  • Trading Symbol: A (New York Stock Exchange)
  • Filer Category: Large Accelerated Filer

Key Financial Highlights

  • Net Income: \$305 million for Q1 2026, compared to \$318 million in Q1 2025.
  • Earnings Per Share (EPS):
    • Basic EPS: \$1.08 (Q1 2026), down from \$1.12 (Q1 2025).
    • Diluted EPS: \$1.07 (Q1 2026), down from \$1.11 (Q1 2025).
  • Total Revenue: Not explicitly disclosed in the visible text; investors should check full statements for the detail.
  • Operating Income: \$353 million (Q1 2026), a decrease from \$376 million (Q1 2025).
  • Research & Development Expenses: \$117 million (Q1 2026), steady year-over-year.
  • Income Tax Expense: \$59 million (Q1 2026), higher than \$49 million in Q1 2025.
  • Comprehensive Income: \$347 million (Q1 2026), up from \$242 million in Q1 2025, primarily due to a significant swing in other comprehensive income (OCI) items.
  • Balance Sheet Strength:
    • Total Assets: \$12.8 billion as of January 31, 2026.
    • Stockholders’ Equity: \$6.9 billion as of January 31, 2026.

Cash Flow and Capital Allocation

  • Operating Cash Flow: \$431 million for Q1 2026.
  • Investing Activities:
    • Capital expenditures of \$93 million.
    • No significant payments for acquisitions or convertible notes in the quarter.
  • Financing Activities:
    • Repurchase of Common Stock: \$152 million.
    • Dividends Paid: \$72 million.
    • Proceeds from Employee Stock Plans: \$31 million.

Important Items and Shareholder Considerations

  • Share Buybacks: Agilent continued to return capital to shareholders through significant share repurchases (\$152 million in Q1 2026). This may provide support to the share price and signals management’s confidence in the company’s valuation.
  • Dividend Policy: The company maintained its dividend payments (\$72 million in Q1 2026), supporting the attractiveness of the stock to income-oriented investors.
  • Moderation in Earnings Growth: There is a slight year-over-year decline in net income and EPS, which investors should monitor. This could weigh on share performance if seen as the beginning of a slowing growth trend.
  • Comprehensive Income: There was a notable increase in other comprehensive income, driven by favorable movements in derivative instruments and OCI items, which contributed to a higher total comprehensive income for the quarter.
  • Balance Sheet Health: Agilent’s financial position remains strong with \$12.8 billion in assets and \$6.9 billion in equity, providing ample flexibility for growth investments, dividends, and buybacks.
  • No Preferred Stock Issued: No preferred stock outstanding, indicating common shareholders are not subordinate to another equity class for dividends or liquidation.

Potential Price-Moving Catalysts

  • Share Buybacks and Capital Returns: The continuation of buybacks and steady dividends can positively influence share valuation.
  • EPS and Net Income Trends: The marginal decline in net income and EPS, though not severe, could be price sensitive if investors interpret it as a sign of growth deceleration.
  • Comprehensive Income Swing: The sharp increase in comprehensive income (including OCI) may positively affect sentiment, especially if driven by improved hedging or investment results.
  • Stable Cash Flows: Healthy operating cash flows support ongoing capital returns and suggest operational resilience.

Conclusion

Agilent Technologies delivered a solid quarter with robust cash flows, ongoing capital returns to shareholders, and a strong balance sheet. While there was a slight dip in EPS and net income, the company’s continued share buybacks and dividends, alongside a positive swing in comprehensive income, are key highlights for investors. The financial results suggest stability and shareholder-friendly capital allocation policies, though investors should monitor earnings trends for any signs of slowing growth.



Disclaimer: The above article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making investment decisions.

View AGILENT TECHNOLOGIES, INC. Historical chart here



Bionano Genomics 2025 Annual Report Highlights: Optical Genome Mapping, Market Expansion, and Risk Factors 57596054

Bionano Genomics 2025 Annual Report - Investor Highlights ...

PDS Biotech Reports 2025 Financial Results and Advances PDS0101 Phase 3 Program with Accelerated Approval Pathway

PDS Biotech Reports 2025 Financials and Key Clinical Updates...

Hurco Companies, Inc. Q1 2026 Quarterly Report: Financial Statements, Analysis, and SEC Filings

Hurco Companies, Inc. Q1 2026 Earnings Report: Key Takeaways...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today